CN111315361A - 作用持续时间更长的用于降低眼内压的持续释放植入物 - Google Patents

作用持续时间更长的用于降低眼内压的持续释放植入物 Download PDF

Info

Publication number
CN111315361A
CN111315361A CN201880072815.7A CN201880072815A CN111315361A CN 111315361 A CN111315361 A CN 111315361A CN 201880072815 A CN201880072815 A CN 201880072815A CN 111315361 A CN111315361 A CN 111315361A
Authority
CN
China
Prior art keywords
implant
lactide
months
patient
bimatoprost
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880072815.7A
Other languages
English (en)
Chinese (zh)
Inventor
M·R·罗宾逊
M·贝贾尼安
M·Y·陈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CN111315361A publication Critical patent/CN111315361A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Surgery (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)
CN201880072815.7A 2017-11-09 2018-11-09 作用持续时间更长的用于降低眼内压的持续释放植入物 Pending CN111315361A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762583967P 2017-11-09 2017-11-09
US62/583,967 2017-11-09
US201862683337P 2018-06-11 2018-06-11
US62/683,337 2018-06-11
PCT/US2018/059910 WO2019094652A1 (en) 2017-11-09 2018-11-09 Sustained-release implants for lowering intraocular pressure with extended duration of effect

Publications (1)

Publication Number Publication Date
CN111315361A true CN111315361A (zh) 2020-06-19

Family

ID=64457124

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880072815.7A Pending CN111315361A (zh) 2017-11-09 2018-11-09 作用持续时间更长的用于降低眼内压的持续释放植入物

Country Status (16)

Country Link
US (2) US20190192341A1 (https=)
EP (1) EP3706717A1 (https=)
JP (2) JP2021502366A (https=)
KR (1) KR20200086289A (https=)
CN (1) CN111315361A (https=)
AU (2) AU2018366214B2 (https=)
BR (1) BR112020009224A2 (https=)
CA (1) CA3080908A1 (https=)
CL (1) CL2020001183A1 (https=)
CO (1) CO2020006924A2 (https=)
IL (1) IL273946A (https=)
MX (2) MX2020004730A (https=)
PH (1) PH12020550550A1 (https=)
RU (1) RU2020113494A (https=)
SG (1) SG11202004126XA (https=)
WO (1) WO2019094652A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105682645B (zh) * 2013-10-31 2019-09-06 阿勒根公司 含前列腺酰胺的眼内植入物及其使用方法
GB2601922B (en) 2019-06-27 2024-04-24 Layerbio Inc Ocular device drub delivery systems
CA3166738A1 (en) 2020-02-06 2021-08-12 Charles D. Blizzard Travoprost compositions and methods for treating ocular diseases
EP3884929B1 (en) 2020-03-25 2023-06-14 Ocular Therapeutix, Inc. Ocular implant containing a tyrosine kinase inhibitor
WO2022011321A1 (en) 2020-07-10 2022-01-13 Allergan, Inc. Posterior chamber delivery device for sustained release implant
BR112023001073A2 (pt) * 2020-07-21 2023-03-07 Allergan Inc Implante intraocular com alto carregamento de prostamida
CN120897764A (zh) 2023-04-11 2025-11-04 视尔普斯眼科公司 包含阿西替尼多晶型物iv的眼部植入物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070224246A1 (en) * 2004-04-30 2007-09-27 Hughes Patrick M Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20120276186A1 (en) * 2011-04-29 2012-11-01 Ghebremeskel Alazar N Sustained release latanoprost implant
CN102821753A (zh) * 2010-01-22 2012-12-12 阿勒根公司 前房内持续释放治疗药植入物
US20150118279A1 (en) * 2013-10-31 2015-04-30 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
CN106132397A (zh) * 2013-12-06 2016-11-16 恩维希亚治疗股份有限公司 用于治疗眼部疾病的前房内植入物
WO2017015675A1 (en) * 2015-07-23 2017-01-26 Envisia Therapeutics, Inc. Glaucoma treatment via intracameral ocular implants

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834498A (en) 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070224246A1 (en) * 2004-04-30 2007-09-27 Hughes Patrick M Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
CN102821753A (zh) * 2010-01-22 2012-12-12 阿勒根公司 前房内持续释放治疗药植入物
CN107184544A (zh) * 2010-01-22 2017-09-22 阿勒根公司 前房内持续释放治疗药植入物
US20120276186A1 (en) * 2011-04-29 2012-11-01 Ghebremeskel Alazar N Sustained release latanoprost implant
US20150118279A1 (en) * 2013-10-31 2015-04-30 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
CN105682645A (zh) * 2013-10-31 2016-06-15 阿勒根公司 含前列腺酰胺的眼内植入物及其使用方法
CN106132397A (zh) * 2013-12-06 2016-11-16 恩维希亚治疗股份有限公司 用于治疗眼部疾病的前房内植入物
WO2017015675A1 (en) * 2015-07-23 2017-01-26 Envisia Therapeutics, Inc. Glaucoma treatment via intracameral ocular implants

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AREF，AHMAD A: "Sustained drug delivery for glaucoma current data and future trends" *
LIU SHENGYAN等: "Nanomaterials for Ocular Drug Delivery" *
RICHARD A.LEWIS等: "Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results From a Phase I/II Clinical Trial" *
左国进等: "曲伏前列素滴眼液治疗原发性开角型青光眼患者的疗效与安全性分析" *
张松瑶等: "新型眼部外用给药系统的研究进展" *
车宁等: "比马前列素滴眼液的药理和临床应用" *

Also Published As

Publication number Publication date
CA3080908A1 (en) 2019-05-16
BR112020009224A2 (pt) 2020-10-13
MX2023011426A (es) 2023-10-17
US20240130890A1 (en) 2024-04-25
JP2024032731A (ja) 2024-03-12
JP2021502366A (ja) 2021-01-28
CO2020006924A2 (es) 2020-06-19
AU2018366214A1 (en) 2020-05-14
PH12020550550A1 (en) 2021-03-22
RU2020113494A3 (https=) 2021-12-09
IL273946A (en) 2020-05-31
RU2020113494A (ru) 2021-12-09
KR20200086289A (ko) 2020-07-16
EP3706717A1 (en) 2020-09-16
US20190192341A1 (en) 2019-06-27
MX2020004730A (es) 2020-08-13
WO2019094652A1 (en) 2019-05-16
AU2018366214B2 (en) 2024-11-14
CL2020001183A1 (es) 2020-11-06
SG11202004126XA (en) 2020-06-29
US20240225893A9 (en) 2024-07-11
AU2024227541A1 (en) 2024-11-14

Similar Documents

Publication Publication Date Title
US20240277609A1 (en) Intraocular pressure reduction with intracameral bimatoprost implants
CN105682645B (zh) 含前列腺酰胺的眼内植入物及其使用方法
US20240225893A9 (en) Sustained-release implants for lowering intraocular pressure with extended duration of effect
US20130071349A1 (en) Biodegradable polymers for lowering intraocular pressure
CA2872338C (en) Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
HK1244665A1 (en) Intraocular pressure reduction with intracameral prostamide implants
HK1244665B (en) Intraocular pressure reduction with intracameral prostamide implants
HK1183436B (zh) 用前房内比马前列素植入物的眼内压降低

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination